Positive results for Microbion’s new diabetic foot ulcer drug

Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI).

The trial demonstrated that the therapy was safe and well-tolerated in patients over a 12-week regimen, marking a positive development for a treatment area in critical need of innovation.

DFIs are a common and serious complication of diabetes, affecting about 15-25% of people with the condition at some point in their lives. Infection can lead to ulcers which can spread to surrounding tissues or bones, sometimes leading to hospitalization and amputations.